Transdermal drug administration dressing powder, transdermal drug administration dressing gel and use method

By combining sodium hyaluronate, poloxamer, and sodium carboxymethyl cellulose, transdermal drug delivery dressing powders and gels are formed, solving the problem of poor drug absorption in existing dressings and achieving effective drug absorption and skin moisturizing effects.

CN115970045BActive Publication Date: 2024-11-12GUANGDONG GENERAL HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211398531.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-12-10
Filing Date
2022-11-09
Publication Date
2024-11-12
Estimated Expiration
2042-11-09

AI Technical Summary

Technical Problem

Existing dressings are difficult to effectively absorb solid or liquid medications, and during use they are prone to drug evaporation or dry, peeling skin. Traditional gel dressings also have poor permeability.

Method used

A combination of sodium hyaluronate, poloxamer, and sodium carboxymethyl cellulose is used to form transdermal drug delivery dressing powders and gels suitable for solid or liquid drugs. By adjusting the mass ratio and particle size, permeability and water content are optimized to promote drug absorption.

Benefits of technology

It enables the effective absorption of solid or liquid drugs, avoids drug evaporation, keeps the skin moist, promotes deep drug absorption, and does not cause dehydration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003934079590000081
    Figure BDA0003934079590000081
Patent Text Reader

Abstract

The present invention relates to the technical field of dressings, and discloses a percutaneous dressing powder, a percutaneous dressing gel and a method of use. The powder contains sodium hyaluronate, poloxamer and sodium hydroxymethylcellulose, and the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 4-12:0.8-1.2:1. The raw material components of the gel contain sodium hyaluronate, poloxamer, sodium hydroxymethylcellulose and water, and the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 4-12:0.8-1.2:1, and the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 500mg, and the amount of the water is 4-8mL. The powder and the gel can be mixed with solid medicaments and can also be mixed with liquid medicaments, and can effectively improve the absorption of the drug by the affected part.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of dressings, and in particular to a transdermal dressing powder, a transdermal dressing gel and a use method thereof. Background Art

[0002] There are many types of diseases, some are suitable for oral medication, and some are suitable for topical medication. When the topical medication is solid, traditional medical dressings represented by bandages or gauze can be used. However, when bandages or gauze are used as medical dressings, it is difficult for the medication to enter the affected area unless there is a wound. When the topical medication is liquid, the medication is easy to evaporate when treated with bandages or gauze, which is not easily absorbed by the epidermis, and the dosage is not easy to control. Long-term use will cause dry skin and peeling.

[0003] In addition, the new dressings sold on the market, such as hydrogel and hydrocolloid dressings, have good moisturizing effects, but the permeability is not very good, which is not conducive to the absorption of drugs by the affected area. Moreover, the gel dressings on the market are all in gel form and can only be used directly or mixed with powders. If mixed with liquids, it will affect the performance of the gel, thereby affecting the use effect of the gel. Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide a transdermal dressing powder, a transdermal dressing gel and a use method. The transdermal dressing powder and the transdermal dressing gel can be mixed with both solid and liquid medicines and can effectively improve the absorption of the medicine by the affected area.

[0005] In order to achieve the above-mentioned object, the first aspect of the present invention provides a transdermal dressing powder, comprising sodium hyaluronate, poloxamer and sodium hydroxymethylcellulose, wherein the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 4-12:0.8-1.2:1.

[0006] Preferably, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:1.

[0007] In a second aspect, the present invention provides a method for using a transdermal dressing powder, wherein sodium hyaluronate, poloxamer, sodium hydroxymethylcellulose and a drug solution for administration are mixed to form a gel;

[0008] Wherein, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 4-12:0.8-1.2:1.

[0009] Preferably, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:1.

[0010] More preferably, based on the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose being 500 mg, the dosage of the drug solution for administration is 4-8 mL.

[0011] In a third aspect, the present invention provides a transdermal dressing gel, wherein the raw material components of the transdermal dressing gel contain sodium hyaluronate, poloxamer, sodium hydroxymethyl cellulose and water, and the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethyl cellulose is 4-12:0.8-1.2:1.

[0012] Preferably, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:1.

[0013] More preferably, based on the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose being 500 mg, the amount of water used is 4-8 mL.

[0014] In a fourth aspect, the present invention provides a method for using a transdermal dressing gel, comprising the following steps:

[0015] (1) mixing sodium hyaluronate, poloxamer, sodium hydroxymethylcellulose and water to obtain a gel;

[0016] Grinding the administration solid into powder to obtain administration powder;

[0017] (2) mixing the drug administration powder with the gel;

[0018] Wherein, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 4-12:0.8-1.2:1.

[0019] Preferably, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:1.

[0020] More preferably, based on the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose being 500 mg, the amount of water used is 4-8 mL.

[0021] Preferably, in step (1), the particle size of the dosing powder is less than or equal to 163 μm.

[0022] Preferably, in step (2), the mass ratio of the dosing powder to the gel is 1:120-130.

[0023] Through the above technical solution, the beneficial effects of the present invention are:

[0024] The percutaneous drug administration dressing powder and percutaneous drug administration dressing gel of the present invention, wherein the powder can be mixed with a drug administration liquid to form a gel, or can be mixed with water to form a gel and then added to a drug administration agent, and is applicable to both liquid and solid agents. The gel formed by combining sodium hyaluronate, poloxamer and sodium hydroxymethylcellulose has an osmotic value closer to the blood osmotic pressure, thereby promoting the absorption of the drug by the epidermis, and has the effects of shrinking the outer layer, replenishing the inner layer, and deep maintenance, and will not cause dehydration. At the same time, the affected area can be isolated from the external air, avoiding the formation of bacteria, and no bandaging is required. DETAILED DESCRIPTION

[0025] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0026] The invention provides a percutaneous administrable dressing powder, which contains sodium hyaluronate, poloxamer and sodium hydroxymethylcellulose, wherein the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 4-12:0.8-1.2:1.

[0027] The inventors found in the course of research that after forming a gel, the sodium hyaluronate, poloxamer and sodium hydroxymethylcellulose in the scope of protection of the present invention interact with each other to make the osmotic value of the prepared gel substantially the same as that of human blood, and the water content thereof changes little during use, thereby promoting the absorption of the drug by the epidermis without causing dehydration. Moreover, the powder can be mixed with a drug solution to form a gel, or mixed with water to form a gel and then added to a drug solution, and is applicable to both liquid and solid drugs.

[0028] Preferably, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10: 0.9-1.1: 1. The inventors of the present invention found during the research process that adjusting the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose to 6-10: 0.9-1.1: 1 can further narrow the gap between the osmotic value of the gel and the osmotic value of human blood and reduce the change in the water content of the hydrogel during use.

[0029] At the same time, the present invention also provides a method for using a percutaneous drug administration dressing powder, wherein sodium hyaluronate, poloxamer, sodium hydroxymethylcellulose and a drug solution for administration are mixed to form a gel;

[0030] Wherein, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 4-12:0.8-1.2:1.

[0031] The above-mentioned drug solution for administration can be a liquid drug used in the prior art for external application, such as timolol maleate eye drops used for treating infantile hemangioma.

[0032] In order to further reduce the change in water content of the hydrogel during use, preferably, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:1.

[0033] The dosage of the above-mentioned drug solution can be determined by those skilled in the art according to actual conditions, as long as it can be mixed to form a gel. In order to further reduce the difference between the gel permeability value and the human blood permeability value, preferably, based on the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose being 500 mg, the dosage of the drug solution is 4-8 mL.

[0034] In addition, the present invention also provides a transdermal dressing gel, which contains sodium hyaluronate, poloxamer, sodium hydroxymethylcellulose and water, and the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 4-12:0.8-1.2:1.

[0035] The inventors discovered during the research process that after adding water to a transdermal dressing powder obtained by combining sodium hyaluronate, poloxamer and sodium hydroxymethylcellulose to form a gel, the sodium hyaluronate, poloxamer and sodium hydroxymethylcellulose within the protection scope of the present invention interact with each other, so that the osmotic value of the prepared gel is substantially the same as the osmotic value of human blood, thereby promoting the absorption of the drug by the epidermis without causing dehydration.

[0036] In order to further reduce the change in water content of the hydrogel during use, preferably, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:1.

[0037] The amount of water can be determined by those skilled in the art according to actual conditions, as long as it can be mixed to form a gel. In order to further reduce the difference between the gel permeability value and the human blood permeability value, preferably, based on the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose being 500 mg, the amount of water is 4-8 mL.

[0038] At the same time, the present invention also provides a method for using the transdermal drug administration dressing gel, comprising the following steps:

[0039] (1) mixing sodium hyaluronate, poloxamer, sodium hydroxymethylcellulose and water to obtain a gel;

[0040] Grinding the administration solid into powder to obtain administration powder;

[0041] (2) mixing the administration powder with the gel;

[0042] Wherein, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 4-12:0.8-1.2:1.

[0043] The solid for administration can be a solid medicine used in the prior art for external application, such as a solid medicine for treating skin diseases. As a specific embodiment of the present invention, the solid for administration is sirolimus tablets, which can be used to treat adult vascular malformations.

[0044] In order to further reduce the change in water content of the hydrogel during use, preferably, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:1.

[0045] The amount of water can be determined by those skilled in the art according to actual conditions, as long as it can be mixed to form a gel. In order to further reduce the difference between the gel permeability value and the human blood permeability value, preferably, based on the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose being 500 mg, the amount of water is 4-8 mL.

[0046] Preferably, in step (1), the particle size of the drug administration powder is less than or equal to 163 μm. The inventors of the present invention have found during research that setting the particle size of the drug administration powder to less than or equal to 163 μm can improve the adsorption effect of the gel on the drug administration powder and also promote the absorption of the drug by the affected area.

[0047] In order to further reduce the difference between the gel permeability value and the human blood permeability value, preferably, in step (2), the mass ratio of the dosing powder to the gel is 1:120-130. In order to further reduce the difference between the gel permeability value and the human blood permeability value, preferably, in step (2), the mass ratio of the dosing powder to the gel is 1:125.

[0048] The present invention will be described in detail below by way of examples. In the following examples,

[0049] Sodium hydroxymethylcellulose, poloxamer, and sodium hyaluronate were purchased from Sinopharm Group; timolol maleate eye drops and sirolimus tablets were obtained from pharmacies.

[0050] The osmotic value was measured by a colloid osmotic pressure measuring instrument (Gonotec, Germany, instrument model OSMOMAT 050); the pH value was measured by a pH meter (Shanghai Sheyan Instrument Co., Ltd., instrument model PHS-2C); the water content was calculated by measuring the mass before and after drying.

[0051] Example 1

[0052] Mix 80 mg of sodium hyaluronate, 10 mg of poloxamer, 10 mg of sodium hydroxymethylcellulose and 1.2 mL of timolol maleate eye drops to form a gel.

[0053] Example 2

[0054] (1) Mix 60 mg of sodium hyaluronate, 11 mg of poloxamer, 10 mg of sodium hydroxymethylcellulose and 1.3 mL of water to form a gel;

[0055] The sirolimus tablets were ground into powder, filtered through a 200-mesh sieve, and the sieved material was taken to obtain a dosing powder;

[0056] (2) Mix the above-mentioned drug-administered powder and the above-mentioned gel at a mass ratio of 1:125.

[0057] Example 3

[0058] Mix 200 mg of sodium hyaluronate, 18 mg of poloxamer, 20 mg of sodium hydroxymethylcellulose and 1.9 mL of timolol maleate eye drops to form a gel.

[0059] Example 4

[0060] (1) Mix 240 mg of sodium hyaluronate, 16 mg of poloxamer, 20 mg of sodium hydroxymethylcellulose and 1.1 mL of water to form a gel;

[0061] The sirolimus tablets were ground into powder, filtered through a 200-mesh sieve, and the sieved material was taken to obtain a dosing powder;

[0062] (2) Mix the above-mentioned drug-administered powder and the above-mentioned gel at a mass ratio of 1:125.

[0063] Example 5

[0064] Mix 40 mg of sodium hyaluronate, 12 mg of poloxamer, 10 mg of sodium hydroxymethylcellulose and 1.2 mL of timolol maleate eye drops to form a gel.

[0065] Example 6

[0066] (1) Mix 24 mg of sodium hyaluronate, 16 mg of poloxamer, 20 mg of sodium hydroxymethylcellulose and 1.1 mL of water to form a gel;

[0067] The sirolimus tablets were ground into powder, filtered through a 150-mesh sieve, and the sieved material was taken to obtain a dosing powder;

[0068] (2) Mix the above-mentioned drug-administered powder and the above-mentioned gel at a mass ratio of 1:125.

[0069] Comparative Example 1

[0070] Mix 40 mg of sodium hyaluronate, 12 mg of poloxamer, and 0.8 mL of timolol maleate eye drops to form a gel.

[0071] Comparative Example 2

[0072] Mix 40 mg of sodium hyaluronate, 10 mg of sodium hydroxymethylcellulose and 0.8 mL of timolol maleate eye drops to form a gel.

[0073] Comparative Example 3

[0074] Mix 24 mg of poloxamer, 20 mg of sodium hydroxymethylcellulose and 0.7 mL of timolol maleate eye drops to form a gel.

[0075] Test Case

[0076] The permeability and pH values ​​of the above-obtained materials were measured, and the obtained data are shown in the following table:

[0077]

[0078] According to the data of the above embodiments and comparative examples, the gel obtained from the powder provided by the present invention and the gel, through the interaction of sodium hyaluronate, poloxamer and sodium hydroxymethyl cellulose within the protection scope of the present invention, can make the osmotic value of the prepared gel between 295-305mmo / L, which is basically the same as the osmotic value of human blood, thereby promoting the absorption of the drug by the epidermis, and the water content of the hydrogel does not change much, which promotes the moisturizing of the epidermis and does not cause dehydration.

[0079] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.

Claims

1. A transdermal dressing, characterized in that: The transdermal drug administration dressing is composed of a powder and a drug administration liquid. The powder contains sodium hyaluronate, poloxamer and sodium hydroxymethyl cellulose. The mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethyl cellulose is 4-12:0.8-1.2:

1. Based on the mass of the powder being 500 mg, the dosage of the drug administration liquid is 4-8 mL.

2. The percutaneous drug administration dressing according to claim 1, characterized in that: The mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:

1.

3. A method for using a percutaneous dressing powder, characterized in that: Mixing sodium hyaluronate, poloxamer, sodium hydroxymethylcellulose and a drug solution for administration to form a gel; The mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethyl cellulose is 4-12:0.8-1.2:1, and the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethyl cellulose is 500 mg, and the dosage of the drug solution is 4-8 mL.

4. The method for using the percutaneous dressing powder according to claim 3, characterized in that: The mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:

1.

5. A transdermal dressing gel, characterized in that: The raw material components of the transdermal dressing gel contain sodium hyaluronate, poloxamer, sodium hydroxymethyl cellulose and water. The mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethyl cellulose is 4-12:0.8-1.2:

1. Based on the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethyl cellulose being 500 mg, the amount of water used is 4-8 mL.

6. The percutaneous dressing gel according to claim 5, characterized in that: The mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:

1.

7. A method for using a transdermal dressing gel, characterized in that: The steps include: (1) mixing sodium hyaluronate, poloxamer, sodium hydroxymethylcellulose and water to obtain a gel; Grinding the administration solid into powder to obtain administration powder; (2) mixing the drug administration powder with the gel; Wherein, the mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethyl cellulose is 4-12:0.8-1.2:1; based on the total mass of the sodium hyaluronate, the poloxamer and the sodium hydroxymethyl cellulose being 500 mg, the amount of water used is 4-8 mL.

8. The method for using the percutaneous dressing gel according to claim 7, characterized in that: The mass ratio of the sodium hyaluronate, the poloxamer and the sodium hydroxymethylcellulose is 6-10:0.9-1.1:

1.

9. The method for using the percutaneous dressing gel according to claim 7 or 8, characterized in that: In step (1), the particle size of the administration powder is less than or equal to 163 μm; In step (2), the mass ratio of the dosing powder to the gel is 1:120-130.